Recently, Endovactec™’s Hector™ Multi-Branch Thoracic Stent Graft System (Hector™) has been approved to enter the Special Review Procedures for Innovative Medical Devices by China’s National Medical Products Administration (NMPA).

Hector™ is designed to enable minimally invasive treatment of complex thoracic aortic aneurysms involving all three supra-aortic branches – an area for which no fully endovascular solutions are currently commercially available. Traditional techniques, such as the chimney and fenestration methods using standard grafts, present significant limitations in such cases. Hector™ addresses this critical clinical challenge with a fully endovascular solution for three-branch reconstruction.

Building on nearly two decades of expertise in branched stent grafts, Endovastec™ introduced the Castor™ system, followed by the Cratos™ system, which featured an enhanced delivery system. Now, as the company’s first multi-branch stent graft, Hector™ further expands endovascular aortic treatment to the entire aortic arch, addressing a significant clinical challenge.

Hector™ integrates several key innovations, including an off-the-shelf triple-branch stent graft design, which is capable of adapting to the variable anatomical structures of the aortic arch, a swift deployment system that preserves supra-aortic vessels blood flow during operation, and a flexible yet stable bridging stent with tip-capture design.

Currently, Hector™ has successfully completed multiple clinical implantations in several countries, including Switzerland and Italy. With fast-track designation by NMPA, Hector™ will become available in China more quickly, supporting broader access to advanced and effective medical solutions.